CAJ | 학술논문

世界人口中约有3.5亿感染乙肝病毒，乙肝病毒感染是急慢性肝炎的主要原因，其与肝纤维化和肝细胞癌的发生密切相关。目前的治疗药物不良反应多或易产生耐药性，因此迫切需要找到新的治疗手段。本文依据近5年来国内外文献进行分析、归纳、总结，综述了治疗HBV感染的小干扰RNA(small RNA interference，siRNA)药物在化学修饰和体内传递方面新进展。RNAi途径可实现病毒基因转录后沉默，特异性和有效性地抑制HBV基因的表达和复制，是治疗HBV感染的一种新颖而有效的途径。而小干扰RNA(siRNA)的化学修饰和体内传递研究，可提高其在体内的稳定性和靶向性。
세계인구중약유3.5억감염을간병독，을간병독감염시급만성간염적주요원인，기여간섬유화화간세포암적발생밀절상관。목전적치료약물불량반응다혹역산생내약성，인차박절수요조도신적치료수단。본문의거근5년래국내외문헌진행분석、귀납、총결，종술료치료HBV감염적소간우RNA(small RNA interference，siRNA)약물재화학수식화체내전체방면신진전。RNAi도경가실현병독기인전록후침묵，특이성화유효성지억제HBV기인적표체화복제，시치료HBV감염적일충신영이유효적도경。이소간우RNA(siRNA)적화학수식화체내전체연구，가제고기재체내적은정성화파향성。
Approximately 350 million of the world's population have hepatitis B virus infection, which is a major cause of acute and chronic hepatitis, and carriers of the virus are at risk for hepatocellular carcinoma and cirrhosis. Current treatment regimens, such as interferon-α and nucleotide analogues are only partially effective and new treatment methods remain an important goal. According to the studies at home and abroad of recent five years, new progress in chemical modification and delivery in vivo of small RNA interference (siRNA) treatment for HBV infection was reviewed. RNAi pathway can induce post-transcriptional gene silencing. The specific and potent suppression of HBV gene expression and replication is a novel and effective way for the treatment of HBV infection. Chemical modification and delivery in vivo study can increase stability and improve targeted delivery.